Key result
Circulating BNP remained significantly increased in heart-transplant recipients compared with matched controls (33.8 vs. 4.0 pg/mL, p=0.002) despite normal hemodynamics and cardiac function.
Why the study?
Does circulating BNP normalize after heart transplantation in patients with normal hemodynamic and right and left heart functions?
Case-Control (n=24)
Does circulating BNP normalize after heart transplantation in patients with normal hemodynamic and right and left heart functions?
Absolute Event Rate: 33.8% vs 4%
p-value: p=0.002
Circulating BNP remains elevated in heart transplant recipients despite normal hemodynamics and cardiac function, suggesting it is not solely a hemodynamic marker in this population.
BNP may remain elevated post-transplant despite normal function, warranting cautious interpretation; leaves open non-hemodynamic mechanisms requiring prospective study.
BACKGROUND: Increased brain natriuretic peptide (BNP) in cardiovascular disease is thought to be a compensatory protective mechanism allowing to delay the occurrence of terminal heart failure. Heart transplantation should normalize the neuroendocrine balance but BNP remains elevated in stable heart-transplant recipients (Htx). Such increase has been related to persistent endothelial and cardiac dysfunctions. The purpose of this study was to determine whether selected Htx, presenting with normal hemodynamic and cardiac systolic and diastolic functions on both side of the heart, show a normalization of their BNP plasma values. METHODS: Of a cohort of well-being 26 Htx, we selected 12 patients with normal hemodynamics and left and right heart systolic and diastolic functions and compared their circulating BNP, cyclic guanosine monophosphate (cGMP) (the BNP second messenger) and endothelin-1 (ET) values with that of 12 age-, body mass index- and mean arterial pressure-matched controls. Cardiac function determination by echodoppler included cardiac filling pressures assessment using tissue Doppler imaging. Blood samples for biological and hormonal determinations were drawn at rest, within 15 min before echocardiography. RESULTS: As selected, hemodynamic and left and right heart systolic and diastolic functions were located in the normal range in Htx. Plasma ET value was also similar in Htx and controls (20.7 +/- 0.9 vs. 19.6 +/- 0.9 fmol/mL). However, circulating BNP, like cGMP, was still significantly increased after heart transplantation, when compared with controls (33.8 +/- 8.5 vs. 4.0 +/- 0.9 pg/mL, p = 0.002 and 8.2 +/- 1.1 vs. 4.4 +/- 0.3 nmol/L, p = 0.003) for BNP and cGMP, respectively, in Htx and controls. Interestingly, the sole correlation observed was between BNP and cGMP (r = 0.85, p < 0.0001) after heart transplantation. CONCLUSIONS: After heart transplantation, BNP remained increased despite the normalization of hemodynamic and cardiac systolic and diastolic functions. This suggests that such endocrine heart stimulation should not be viewed only as a hemodynamic marker in Htx. Further studies will be useful to investigate the role of pro-inflammatory cytokines and whether elevated BNP still possesses antifibrotic properties, further supporting the interest of enhancing its activity after heart transplantation.
No takes yet. Share an insight, caveat, or question.
Talha et al. (2008) conducted a case-control in Heart transplantation (n=24). Heart transplantation vs. Age-, BMI-, and MAP-matched controls was evaluated on Circulating BNP (pg/mL) (p=0.002). Circulating BNP remained significantly increased in heart-transplant recipients compared with matched controls (33.8 vs. 4.0 pg/mL, p=0.002) despite normal hemodynamics and cardiac function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: